Clinical Trial Imaging Market worth $2.07 billion by 2029
The report "Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029", is projected to reach USD 2.07 billion by 2029 from USD 1.42 billion in 2024, at a CAGR of 7.8%.
Browse 311 market data Tables and 48 Figures spread through 248 Pages and in-depth TOC on "Clinical Trial Imaging Market by Software & Service (Operational Imaging, Trial Design), Modality (CT, MRI, X-Ray, PET, Ultrasound), Therapeutic Area (Infectious, Oncology, CNS, CVD), End User (Pharma, Biotech, CROs) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/clinical-trials-imaging-market-30446624.html
Increasing R&D spending in drug discovery/imaging/procedure development, the growth of the biotechnology and pharmaceutical industries, subsequent rise in the number of clinical trials carried out and the rise of Contract Research Organizations (CROs) number willing to carry on R&D are among other contributing reasons for the growth of clinical trial imaging market. Market participants in clinical trial imaging find appealing opportunities in developing nations like China, India, and Japan. The restraining factor in the growth of the market is the implementation cost of the imaging devices. Such hinderance can slow down the market a notch
The services segment accounted for the largest share of the clinical trial imaging market, by service and software segment, in 2023
The clinical trial imaging market is divided into two segments: services and software, based on services and software. Services held the most market share for clinical trial imaging worldwide in 2023. Depending on the therapeutic area, region of interest, and drug candidate properties, various image modalities may be required during clinical evaluation. These comprise CT, MRI, ultrasound, PET, X-ray, and ECHO. The high cost of imaging equipment, which has forced pharmaceutical, biotechnology, and medical device makers to outsource their imaging clinical trials to service providers, is largely to blame for this segment's size
Positron emission tomography segment to register the highest growth rate during the forecast period
Computed tomography, magnetic resonance imaging, ultrasound, positron emission tomography, X-ray, and other modalities are the segments that make up the clinical trial imaging market. By 2023, the segment with the fastest growth rate was positron emission tomography. It is anticipated that advances in technology and the development of novel tracers for use in neurology, cardiology, and oncology will encourage the use of PET systems in clinical trial settings. Also, Factors such as the rising incidence of CVDs, the growing prevalence of lifestyle and age-related disorders, such as hypertension, obesity, dyslipidemia, and diabetes, the increasing availability of cardiac CT devices in major markets, and technological advancements drive segment growth.
The oncology segment accounted for the largest share of the clinical trial imaging market, by therapeutic area segment, in 2023
The therapeutic areas of oncology, infectious diseases, neurology, CVS, endocrinology, immunological disorders, and other therapies are the divisions of the clinical trial imaging market. By 2023, the clinical trial imaging market was dominated by the oncology category. The significant percentage of this segment's market share can be primarily ascribed to the large number of clinical trials connected to oncology, which are being pushed by the rise in cancer incidence worldwide.
North America is the largest regional market for clinical trial imaging market
There are five main regions that make up the global market for clinical trial imaging: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the Gulf Cooperation Council. North America held the most market share for clinical trial imaging in 2023. The expanding number of biotechnology and pharmaceutical companies, the growing amount of advanced medical technologies, and the significant government spending in clinical research and development are all responsible for this region's size.
The major players operating in this market are ICON plc. (Ireland), Medpace Holdings, Inc. (US), IXICO plc. (UK), Resonance Health Ltd. (Australia), Radiant Sage LLC. (US), Intrinsic Imaging LLC. (US), Cardiovascular Imaging Technologies LLC. (US), Medical Metrics Inc. (US), Prism Clinical Imaging, Inc. (US), Boston Imaging Core Lab LLC. (US), anagram 4 clinical trials (Spain), Lyscaut Medical Imaging Company (Belgium), Calyx Group (UK), Bioseptive Inc. (Canada), ProScan Imaging LLC. (US), Micron Inc. (Japan), Imaging Endpoints LI, LLC (US), Perspectum Ltd. (UK), Pharmtrace klinische Entwicklung GmbH (Germany), WorldCare Clinical, LLC (US), Median Technologies (France) and Invicro. LLC. (US).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Clinical Trial Imaging Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
